Jimenez v. U.S. Immigration and Customs Enforcement

District Court, N.D. California·Decided May 20, 2024·No. 1:23-cv-06353·Unknown

Opinion

VICTOR JIMENEZ, et al., Case No. 23-cv-06353-RMI

Plaintiffs, ORDER RE: PENDING MOTIONS v. Re: Dkt. Nos. 21, 21, 50 ENFORCEMENT, et al., Defendants. Now pending before the court is Plaintiffs’ First Amended Complaint (“FAC”) (dkt. 68), Plaintiffs’ Motion for Preliminary Injunction (dkt. 20), Plaintiffs’ Motion to Certify Class (dkt. 21), and Defendants’ Motion to Dismiss (dkt. 50). The matters have been fully briefed (see dkts. 50, 52, 53, 55, 57, 58, 59), and the Parties have presented their positions at oral argument (see dkt. 71). For the reasons stated below, Plaintiffs’ motions are denied without prejudice, Defendant’s motion is granted, and the FAC is dismissed with leave to amend. Plaintiffs Victor Jimenez, Venancio Esteban Riego, and Jose Orozco Cuevas, bring this case on behalf of themselves and other similarly situated persons and claim that Defendants (two named officials of U.S. Immigration and Customs Enforcement) (“ICE”) have failed to provide frequent testing for COVID-19 and antiviral medications to medically vulnerable immigrants detained at the Golden State Annex (or “GSA”). See FAC (dkt. 68) at 1-2. The court takes all of the FAC’s plausible allegations as true. Plaintiffs are medically vulnerable individuals detained at GSA, while they await adjudication of their civil immigration cases. Id. at ¶ 4. Due to the close detention than in the general public. Id. at ¶ 5. In addition to the preventative measures of COVID- 19 vaccines, several antiviral treatments have also been developed – Paxlovid and Lagevrio can be taken orally, while Veklury can be taken via intravenous infusion at a healthcare facility. Id. at ¶ 2. Plaintiffs state that “if they were to contract COVID-19, [they] want to receive COVID-19 antiviral medications; however, Plaintiffs and others in ICE detention have previously been denied antiviral medications after testing positive for COVID-19.” Id. at ¶ 6. The FAC goes on to state that notwithstanding the fact “that ICE detains a large number of people who are medically vulnerable to serious illness and death from COVID-19, and despite knowing that antiviral medication is critically important to the treatment of COVID-19, Defendants have failed to ensure that people in their custody nationwide can receive antiviral medication in accordance with CDC and National Institutes of Health (“NIH”) guidance.” Id. at ¶ 7. Defendants have issued post-pandemic guidelines to the effect: that antiviral medication treatment is effective against a particular variant of SARS-CoV-2; that antiviral medication reduces the risk of progression to severe disease; that it decreases the need for hospitalization; and that it reduces the severity of disease thereby improving survival. Id. at ¶ 8. However, rather than dispensing the medicine upon every single positive test, Defendants have only recommended that each detainee newly diagnosed with COVID-19 be assessed for possible antiviral treatment. Id. Plaintiffs allege that this recommendation is insufficient because “people with medical vulnerabilities have tested positive for COVID-19 while held at Golden State Annex and have not been offered COVID-19 antivirals.” Id. Consequently, the FAC alleges that Defendants’ policy of not automatically offering antiviral treatment upon a positive test for COVID-19 to Plaintiffs and the putative class (that is, all civil immigration detainees over the age of 50 who have medical conditions that the CDC recognizes as medically vulnerable to COVID-19) places them at an unreasonable risk of serious illness and death and constitutes an unlawful punishment of the members of the class members. Id. at ¶ 9. Plaintiffs add that the effectiveness of these antiviral medications depends on their prompt administration after symptom onset and requires robust testing and symptom-monitoring protocols Annex. Id. at ¶ 10. Furthermore, they allege that because ICE considers the status at the Golden State Annex to be “green,” the COVID-19 screening protocols are relaxed to only require that individuals detained there receive temperature checks and verbal symptoms screenings during the intake process. Id. If detainees newly admitted to the Golden State Annex are identified with an elevated temperature or COVID-like symptoms, only then are they tested for COVID-19; however, at other facilities designated with a “red” status, all new detainees are tested for COVID- 19 at the time of their admission. Id. The ICE “guidelines do not require periodic testing of individuals detained at GSA unless those individuals present with COVID-like symptoms or are determined to have come in contact with an individual who has tested positive for COVID-19.” Id. at ¶ 11. Appearing to narrate anecdotal evidence – but without specifying whether the anecdote refers to any known individuals (including Plaintiffs) or specifying the ultimate outcome of the anecdote – the FAC states that: “even when individuals at the facility have reported symptoms, GSA personnel have ignored the risk that those individuals may have COVID-19, instead suggesting that the symptoms may be for other reasons, like sinus problems[,and] [i]n those instances, medically vulnerable individuals with COVID-19 have waited days, or even weeks, before they were tested for COVID-19, rendering these individuals ineligible for antiviral medication under the CDC and NIH guidelines.” Id. The FAC does not venture to describe anything further about the persons involved in this anecdote – that is, whether their COVID-19 tests were positive or negative, whether their illness was mild or severe, or whether the identified symptom was or was not due to sinus problems after all. Plaintiffs then add that “[w]ithout prompt and adequate testing and provision of COVID- 19 antiviral medication, Plaintiffs and Class Members lack adequate protection against serious illness and death from COVID-19[, and] [t]his Court should order Defendants to immediately make available and provide Plaintiffs and all similarly situated individuals held at GSA with antiviral medication, by directing GSA to identify medically vulnerable people in Defendants’ custody, timely test them for COVID-19, and provide them with antiviral medication upon their As to the medications, Plaintiffs note that Paxlovid has been shown to reduce the risk of COVID-19 hospitalization and death of symptomatic, unvaccinated people who are at high risk for severe COVID-19 by 89%, while reducing the risk of hospitalization for vaccinated individuals or those with prior infections by 51%. Id. at ¶ 27. Those who are unable to take Paxlovid due to a medical complication may be treated with alternatives such as Veklulry (Redemsivir) or Lagevrio (Molnupiravir). Id. at ¶ 28. The FAC alleges that Lagevrio should be taken within five days of symptom onset and Veklury should be taken within seven days of symptom onset. Id. However, the FAC is silent about the potential implications, if any, involved with being administered Paxlovid, Lagevrio, or Veklury later than five or seven days after the onset of symptoms, or whether there would be a difference in cases where the person was vaccinated or unvaccinated, or in cases where the symptoms were mild versus severe. In any event, Plaintiffs allege that these antiviral medicines are widely available, and that the federal government maintains an ample supply “with millions of treatment courses still in the field.” Id. at ¶ 30. Without specifying their vaccination status, Plaintiffs each allege that they are medically vulnerable to severe COVID-19 and face an unreasonable risk of serious illness and death from COVID-19 without the critical treatment option of antiviral medication. Id. at ¶ 31. Plaintiff Jimenez has a history of hypertension and is “currently on five different kinds of medication to treat his cardiovascular issues.” Id. at ¶ 32 Plaintiff Orozco Cuevas also has hypertension; and Plaintiff Riego has hypertension, diabetes, an aneurysm, an

Free access — add to your briefcase to read the full text and ask questions with AI

Jimenez v. U.S. Immigration and Customs Enforcement, (N.D. Cal. 2024).

Jimenez v. U.S. Immigration and Customs Enforcement (Jimenez v. U.S. Immigration and Customs Enforcement) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Chandler v. State Farm Mutual Automobile Insurance
598 F.3d 1115 (Ninth Circuit, 2010)
Regional Rail Reorganization Act Cases
419 U.S. 102 (Supreme Court, 1974)
Warth v. Seldin
422 U.S. 490 (Supreme Court, 1975)
Bell v. Wolfish
441 U.S. 520 (Supreme Court, 1979)
Babbitt v. United Farm Workers National Union
442 U.S. 289 (Supreme Court, 1979)
Youngberg v. Romeo Ex Rel. Romeo
457 U.S. 307 (Supreme Court, 1982)
Thomas v. Union Carbide Agricultural Products Co.
473 U.S. 568 (Supreme Court, 1985)
Lujan v. Defenders of Wildlife
504 U.S. 555 (Supreme Court, 1992)
Maya v. Centex Corp.
658 F.3d 1060 (Ninth Circuit, 2011)
Oscar W. Jones v. Lou Blanas County of Sacramento
393 F.3d 918 (Ninth Circuit, 2004)
Marder v. Lopez
450 F.3d 445 (Ninth Circuit, 2006)
Alcoa, Inc. v. Bonneville Power Administration
698 F.3d 774 (Ninth Circuit, 2012)
David Pride, Jr. v. M. Correa
719 F.3d 1130 (Ninth Circuit, 2013)
Bova v. City of Medford
564 F.3d 1093 (Ninth Circuit, 2009)
Spokeo, Inc. v. Robins
578 U.S. 330 (Supreme Court, 2016)
Kelvin Hernandez Roman v. Chad Wolf
977 F.3d 935 (Ninth Circuit, 2020)
Garland v. Gonzalez
596 U.S. 543 (Supreme Court, 2022)
Clinton v. Acequia, Inc.
94 F.3d 568 (Ninth Circuit, 1996)